What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Valérie Boige mostly deals with Internal medicine, Colorectal cancer, Surgery, Oncology and Chemotherapy.
In her research, Surgical oncology is intimately related to Gastroenterology, which falls under the overarching field of Internal medicine.
Her work carried out in the field of Colorectal cancer brings together such families of science as Cancer research, Metastasis and Immunology.
Valérie Boige combines subjects such as Primary tumor and Peritoneal carcinomatosis with her study of Surgery.
Her Oncology study combines topics in areas such as Hepatocellular carcinoma, Sorafenib, Pharmacology and Bioinformatics.
Her Chemotherapy course of study focuses on Regimen and Adenocarcinoma, Hazard ratio and Perioperative.
Her most cited work include:
- KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer (1905 citations)
- The consensus molecular subtypes of colorectal cancer (1870 citations)
- KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab (1279 citations)
What are the main themes of her work throughout her whole career to date?
Valérie Boige mainly focuses on Internal medicine, Oncology, Colorectal cancer, Chemotherapy and Gastroenterology.
Her research brings together the fields of Surgery and Internal medicine.
Her Oncology research incorporates elements of Survival rate, Hepatocellular carcinoma, Sorafenib and Regimen.
Her Colorectal cancer research is included under the broader classification of Cancer.
Valérie Boige interconnects Radiation therapy, Clinical trial, Adjuvant, Prospective cohort study and Survival analysis in the investigation of issues within Chemotherapy.
Her work carried out in the field of Gastroenterology brings together such families of science as Liver cancer, Neutropenia, Phases of clinical research and Confidence interval.
She most often published in these fields:
- Internal medicine (68.11%)
- Oncology (45.85%)
- Colorectal cancer (45.85%)
What were the highlights of her more recent work (between 2018-2021)?
- Internal medicine (68.11%)
- Oncology (45.85%)
- Colorectal cancer (45.85%)
In recent papers she was focusing on the following fields of study:
Valérie Boige spends much of her time researching Internal medicine, Oncology, Colorectal cancer, Chemotherapy and Oxaliplatin.
Her Internal medicine study frequently draws connections between adjacent fields such as Gastroenterology.
Her work is dedicated to discovering how Oncology, Toxicity are connected with Clinical significance and other disciplines.
The concepts of her Colorectal cancer study are interwoven with issues in Cancer research and Radiology.
Her Malignant Peritoneal Mesothelioma study in the realm of Chemotherapy interacts with subjects such as Proof of concept.
Her research in Oxaliplatin intersects with topics in Clinical endpoint and Chemoradiotherapy.
Between 2018 and 2021, her most popular works were:
- Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial. (53 citations)
- Molecular targeted therapy of BRAF-mutant colorectal cancer (32 citations)
- Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab. (26 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Her primary scientific interests are in Colorectal cancer, Internal medicine, Oncology, Oxaliplatin and Cancer.
Her studies deal with areas such as Bevacizumab and Neoadjuvant therapy as well as Colorectal cancer.
Internal medicine is often connected to Gastroenterology in her work.
As part of her studies on Oncology, Valérie Boige often connects relevant areas like Chemotherapy.
Her work investigates the relationship between Cancer and topics such as Cancer research that intersect with problems in Mesenchymal stem cell, Gene, PRNP, Transcriptome and Phenotype.
The various areas that Valérie Boige examines in her Irinotecan study include Cetuximab, Targeted therapy and Prospective cohort study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
